Commercialization in China through partnership with SciClone Pharmaceuticals
Enters into Strategic Transaction, unlocking $100 million in value
NASHVILLE, Tenn. , April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that it will release its first quarter 2026...
Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential...
A Safe and Effective Non-Opioid Pain Management Solution
Sancuso – the Difference Between Life and Living
Cumberland to highlight 2025 financial, international, portfolio and clinical progress